The purpose of the Administration Core is to support the translational research objectives of the UCLA SPORE in Prostate Cancer by serving as the organizational hub. The Core is responsible for the oversight of our SPORE by providing scientific leadership and administration for the proposed translational research projects, shared core resources. Developmental Research (DRP) and Career Development Programs (CDP). The overall Specific Aims are: 1) Organizational leadership for successful SPORE conduct;2) Oversight and administrative support for daily SPORE activities;3) Scientific management of the SPORE, including scientific review of projects and cores to ensure scientific goals are met;4) Administration of the DRP and CDP;5) Responsibility for maintaining fiscal and budgetary functions;6) Organization and conduct of regular SPORE meetings and seminars. Including the Annual UCLA SPORE in Prostate Cancer Symposium, quarterly investigator meetings, attendance at the NCI Translational Science meeting and relevant NIH/NCI workshops;7) Compliance with all UCLA, NCI, and Federal regulations and requirements including appropriate animal subject approval maintenance, appropriate human subject approval maintenance, and minority inclusion policy monitoring;8) A Data/Resource Sharing Plan implemented by project and core investigators;9) Liaison service for SPORE investigators, collaborators, and committee members, including the External Advisory Board (EAB), Internal Advisory Board (IAB), Executive Committee and Patient Advocacy Group, and responsibility for communication and consultation with the NCI-TRP program officer and staff;10) Implement and monitor recommendations of the External Advisory Committee, Internal Advisory Board, Executive Committee, CDP and DRP committees within the SPORE. The Administration Core is led by Robert Reiter, MD, the SPORE principal investigator, who oversees all SPORE activities. The Core's co-director is Owen Witte, MD. The Administration Core also includes expert personnel in general university operations, grants administration, financial management, computer network support and general administrative duties.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Los Angeles
Los Angeles
United States
Zip Code
Nagarajan, Mahesh B; Raman, Steven S; Lo, Pechin et al. (2018) Building a high-resolution T2-weighted MR-based probabilistic model of tumor occurrence in the prostate. Abdom Radiol (NY) 43:2487-2496
Calais, Jeremie; Fendler, Wolfgang P; Eiber, Matthias et al. (2018) Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. J Nucl Med 59:434-441
Vidal, Adriana C; Howard, Lauren E; de Hoedt, Amanda et al. (2018) Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database. Cancer Causes Control 29:581-588
Vidal, Adriana C; Howard, Lauren E; de Hoedt, Amanda et al. (2018) Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int 122:76-82
Jelinek, David; Flores, Aimee; Uebelhoer, Melanie et al. (2018) Mapping Metabolism: Monitoring Lactate Dehydrogenase Activity Directly in Tissue. J Vis Exp :
Lee, John K; Bangayan, Nathanael J; Chai, Timothy et al. (2018) Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer. Proc Natl Acad Sci U S A 115:E4473-E4482
Mitra, Mithun; Lee, Ha Neul; Coller, Hilary A (2018) Determining Genome-wide Transcript Decay Rates in Proliferating and Quiescent Human Fibroblasts. J Vis Exp :
Zou, Yongkang; Qi, Zhi; Guo, Weilong et al. (2018) Cotargeting the Cell-Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3K?/?/? Inhibitor BAY1082439. Mol Cancer Ther 17:2091-2099
Henning, Susanne M; Galet, Colette; Gollapudi, Kiran et al. (2018) Phase II prospective randomized trial of weight loss prior to radical prostatectomy. Prostate Cancer Prostatic Dis 21:212-220
Miller, Eric T; Salmasi, Amirali; Reiter, Robert E (2018) Anatomic and Molecular Imaging in Prostate Cancer. Cold Spring Harb Perspect Med 8:

Showing the most recent 10 out of 339 publications